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Hormonal and Barrier Methods of Contraception,
Oncogenic Human Papillomaviruses, and Cervical
Squamous Intraepithelial Lesion Development
ANN L. COKER, Ph.D.,1 LAURA C. SANDERS, M.S.P.H.,2
SHARON M. BOND, C.N.M., M.S.N.,3 TSILYA GERASIMOVA, Ph.D.,4
and LUCIA PIRISI, M.D.4

ABSTRACT
We assessed the influence of hormonal (oral, injectable, or levonorgestrel [Norplant, WyethAyerst, Philadelphia, PA]) and barrier methods of contraception on the risk of cervical squamous intraepithelial lesions (SIL), while adjusting for high-risk (HR) HPV infection. Subjects were women receiving family planning services through the state health department
clinics from 1995 to 1998. We selected 60 cases with high-grade cervical/SIL (HSIL) and 316
with low-grade cervical/SIL (LSIL) and controls (427 women with normal cervical cytology)
and analyzed cervical DNA for HR-HPV, using Hybrid Capture I (Digene; Gaithersburg, MD).
When assessing ever use, duration, recency, latency, and age at first use, neither oral contraceptives (OC), Norplant, nor injectable use was associated with an increased risk of SIL development after adjusting for age, age at first sexual intercourse, and HR-HPV positivity.
Among HR-HPV-positive women, longer duration barrier method use was associated with a
reduced risk of SIL. This finding has important clinical implications for SIL prevention among
HR-HPV-infected women.
INTRODUCTION

U

of contraception in
cervical neoplasia development is a methodological challenge. 1–3 Risk of disease differs by
type of contraceptive used. Barrier methods may
reduce the risk of cervical squamous intraepithelial lesions (SIL), whereas hormonal methods may
increase SIL risk. Selection bias may be important
in studies of preinvasive disease if, for example,
oral contraceptive (OC) users are more likely to be
NDERSTANDING THE ROLE

screened and potentially detected as having SIL
than are nonusers. Additionally, if controls are
sampled from demographically different populations than are cases, selection bias may further affect the internal study validity. Investigators must
assess the potentially confounding effect of highrisk human papillomavirus (HR-HPV) positivity4–12 when evaluating the role of contraception
in cervical neoplasia development. Other confounding factors include smoking, sexual behavior of the woman and her partner, and parity.
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Several epidemiological studies have addressed the role of OC in SIL,9,13–20 cervical
carcinoma in situ (CIS),3,17,21–25 and invasive cervical cancer (ICC) development.7,17,26– 36 The majority of such studies find an increased risk of
ICC7,16,28,30– 32,34,36,37 and CIS3,21,23–25 associated
with long-term (.5 years) and with recent OC
use. OC have not been consistently linked with
lower-grade cervical lesions.9,13–20 Because of the
potential for detection and confounding bias in
explaining study results, Grimes 38 suggests that
making the case for a causal role of OC in cervical neoplasia is difficult. Further, only the more
recent studies were able to assess HPV positivity,
a major etiological agent in cervical neoplasia,
which may confound or modify the association
between contraceptive use and cervical neoplasia
development.
Barrier methods have been linked to a reduced
risk of low-grade SIL (LSIL),9,13,20,39 high-grade
SIL (HSIL),40,41 CIS,22 and ICC.24,25,41– 43 Three
large case-control studies of injectable hormonal
contraceptive use, reviewed by LaVecchia, 44
found no strong evidence of an association with
cervical neoplasia. 13,45–47 Levonorgestrel implants (Norplant, Wyeth-Ayerst, Philadelphia,
PA) have only recently be widely available, and
three follow-up studies of users have found no
increased risk of cervical SIL.48-50
The purpose of this case-control study, nested
in a cohort of young, low-income women seeking family planning services in a rural state, was
to examine whether hormonal or barrier contraceptives were associated with cervical SIL, controlling for HR-HPV types and risk taking behaviors.

MATERIALS AND METHODS
Subjects
Cases and controls for this study were women
receiving family planning services through South
Carolina health department clinics from 1995 to
1998. At the time the Pap smear was collected, an
additional cervical sample was collected and
stored for subsequent evaluation. We conducted
HPV typing on a subset of stored cervical samples depending on the women’s cervical cytology. We sampled as cases all those whose Pap
smear indicated SIL; 60 women had HSIL and 316
women had LSIL. For this analysis, we excluded

as cases and controls women with ASCUS or AGCUS on their Pap smear. We included as controls
women who had normal cervical cytology on the
index Pap smear and no history of treatment for
an abnormal Pap smear. Because many women
had normal Pap smears (eligible controls), we selected a subsample from this control pool, approximately equal to the number of SIL cases, for
interview and HPV typing (n 5 427). We excluded women with a history of treatment for cervical neoplasia. The age range of subjects was
16–45 years. This case-control study is part of a
larger cohort study of HR-HPV and SIL development. Subjects were interviewed to obtain data
on medical, reproductive, and sexual history,
specifically contraceptive use, alcohol and tobacco use, and physical activity.

Response rate
Of 1052 attempted interviews (458 SIL cases
and 594 controls), we were able to complete interviews with 76% of subjects (82% of cases and
72% of controls). We could not locate 17% (13%
of cases and 17% of controls), and 7% (5% of cases
and 10% of controls) refused. The number of attempted interviews included all eligible women.
There were no significant differences in response
rates (refusals, could not locate, or completed interview) by race. Among the nonrespondents,
57% were African American and 41% were white.
Nonresponders, however, were younger than responders. As our population is very mobile, is relatively young, and has a low income, we believe
our response rate is appropriate. The total sample size included in these analyses is 376 SIL cases
and 427 controls.
Sampled cases and controls were interviewed
by telephone (56.3%) or in person (43.7%). On
completion of the 15–20-minute interview, we
mailed subjects $10 for their time. The University
of South Carolina Institutional Review Board approved this project, and all women included in
these analyses provided informed consent for
study participation.

Contraceptive history by method, including ever
use, duration, latency, and recency
We obtained detailed contraceptive histories in
telephone or in-person interviews. For each contraceptive method (OC, Norplant, injectables, intrauterine devices [IUD], and barrier methods, in-
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cluding condoms, spermicides, and diaphragms),
we asked about consistent use for at least 6
months, age at first use, last use, and total duration of use. We created duration, latency, and recency indices for each method. Recency was defined as current users (within the past year) or
those no longer using the method at the time of
interview (.1 year since last use). OC method
users, in particular, are required to have Pap
smears to remain on this method. This linkage of
contraceptive exposure with screening for SIL
may lead to a detection bias and is the reason we
specifically addressed recency of contraceptive
method use. Latency was defined as the time
since first contraceptive method use (current age
minus age at first contraceptive method use). To
be etiologically linked to SIL, we hypothesized
that contraceptive use must have begun at least
2 years prior to SIL development.
As indicated in Table 1, the majority (85%) of
women had ever used OC. We, therefore, could
not create mutually exclusive categories of contraceptive use. Instead, we opted to adjust for barrier method use (condoms, spermicides, or diaphragm use) when evaluating hormonal
contraceptive use, and vice versa. To illustrate, of
414 barrier method users, 84% had also used OC,
of 63 Norplant users, 79% were also OC users,
and of 166 injectable contraceptive users, 69% had
also used OC. There were too few women who
had ever used IUDs to evaluate the risk of SIL associated with IUDs.
Other risk factors assessed in the interview included age, race, employment, education, and
current marital status; reproductive history, including number of pregnancies, pregnancy outcomes, mode of delivery, and infertility; sexual
history, including age at first sexual intercourse,
number of male sex partners, number of sex partners of the current partner; active and passive
smoke exposure; and a brief medical history, including sexually transmitted infections by type.

HPV analyses
A cervical sample for subsequent HPV typing
using Hybrid Capture I (Digene; Gaithersburg,
MD) was collected from each woman before the
Pap smear was taken. This sample was collected
and stored in a Virapap transport buffer medium
developed by Digene. Samples were stored in
freezers until case status could be determined.
DNA was extracted from cervical smear samples
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using standard procedures, and PCR amplification for b-globin DNA sequences was performed
to determine if sufficient cervical DNA was present in the sample. A unique study number was
assigned to each cervical sample. Samples were
sent to L.P.’s laboratory for analysis. To minimize
differential misclassification, those conducting
HPV analyses were blinded to subjects’ cervical
disease status.
HR-HPV positivity was determined using Hybrid Capture I techniques according to the manufacturer’s guidelines. The same person (T.G.)
conducted HPV typing for all samples. We assessed high-risk (HPV16, 18, 31, 33, 35, 45, 51, 52,
and 56) and low-risk types (HPV6, 11, 42, 43, and
44). For this analysis, we focused solely on HRHPV positivity. HR-HPV positivity indicates that
the case or control had one of the range of oncogenic HPV viral types in her cervix at the time
the sample was collected. We do not have
prospective measures of HPV positivity for this
analysis.

Statistical analysis
All statistical analyses were performed using
SAS version 6.12 . We assessed confounding by
examining the association between possible confounders and case or control status. Age, age at
first sexual intercourse, and HR-HPV status
were significantly associated with SIL status and
were, therefore, included as confounders in subsequent models. Additionally, because women
frequently use more than one method of contraception and barrier methods are thought to
reduce SIL risk whereas long-term hormonal use
may increase risk, we included as confounders
ever use and duration of other methods of contraception in subsequent models. Not adjusting
for barrier method use, for example, could bias
the resulting relative risk estimate for hormonal
contraceptive use away from the null. Multiple
logistic regression models51 were used to estimate the relative risk for contraceptive methods
and SIL development, adjusting for these three
confounders and other contraceptives (Table 2)
and within strata of HR-HPV positivity (Table
3). Contraceptive use is presented as having
used the method consistently for at least 6
months. The categories are not mutually exclusive, and we do control for barrier method use
when evaluating hormonal contraceptive use,
and vice versa.
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RESULTS
Table 1 shows the demographic profile of clinic
clients. Only low-income women are eligible to
receive family planning services through health
department clinics. Thus, all these women have
low incomes. Sixty-one percent of the women

TABLE 1.

DEMOGRAPHIC

AND

were African American, and the rest were white,
not Hispanic. The mean age at interview was 26.1
years (standard deviation [SD] 6.1 years). SIL
cases were significantly younger than controls.
Cases had an earlier age at first sexual intercourse
and were more likely to have had any type of sexually transmitted infection, specifically to have

RISK FACTOR PROFILE OF SIL CASES AND CONTROLS RECRUITED
HEALTH DEPARTMEN T CLINICS , 1995–1998 (n 5 803)

Age, years
Number of pregnancies
Age at first sexual intercourse
Lifetime number of male sex partners
Marital status
Divorced/separated
Married
Single b
Ever pregnant
Never pregnant b
Race
African American
Whiteb
Education
#High school
.High schoolb
Unemployed
Employed or studentb
Partner infidelity
No known partner infidelity b
Self-reported history of a sexually
transmitted infection by type
Any
Genital warts
Gonorrhea
Pelvic inflammatory disease
Human immunodeficiency virus (HIV)
High-risk HPV positive
Smoking status
Ever smoker
Never smoker b
Current smoker
Ever used contraceptives regularly for
6 months or longer by type
Oral contraceptives (OC)
Intrauterine device (IUD)
Injectables
Norplant
Barrier methods
Condoms/spermicides
Diaphragm

HSIL
(n 5 60)

LSIL
(n 5 316)

24.5 6 5.7a,**
01.3 6 1.3***
15.8 6 2.4*
05.8 6 5.0

25.4 6 6.2**
01.5 6 1.4***
016.0 6 2.6***
06.5 6 6.5

%

(n)

%

(n)

15.0
30.0
55.0
70.0
30.0

(9)
(18)
(33)
(42)
(18)

17.7
25.0
57.2
69.6
30.4

(56)
(79)**
(181)
(220)
(96)

FROM

SOUTH CAROLINA
Controls
(n 5 427)
28.1
01.7
16.7
06.1

6 6.5
6 1.6
6 3.0
6 6.6

%

(n)

13.1
35.1
51.8
74.7
25.3

(56)
(150)
(221)
(319)
(108)

58.3 (35)
41.7 (25)

62.3 (197)
37.7 (119)

59.5 (254)
40.5 (173)

55.0
45.0
28.3
71.7
76.7
23.3

(33)
(27)
(17)
(43)
(46)*
(14)

63.9
36.1
31.6
68.4
63.6
36.4

(202)
(114)
(100)
(216)
(201)
(115)

57.4
42.6
29.3
70.7
63.0
37.0

(245)
(182)
(125)
(302)
(269)
(158)

48.3
13.3
13.3
6.7
0.0
65.0

(29)*
(8)*
(8)
(4)
(0)
(39)**

40.8
10.8
10.4
9.2
0.9
44.9

(129)*
(34)*
(33)
(29)
(3)
(142)**

34.9
6.6
9.1
8.0
1.6
18.3

(149)
(28)
(39)
(34)
(7)
(79)

35.0 (21)
65.0 (39)
30.0 (18)

32.6 (103)
67.4 (213)
24.1 (76)

32.1 (137)
67.9 (290)
23.9 (102)

78.3
1.7
26.7
3.3
48.3
45.0
1.7

85.4
1.9
18.7
9.5
57.9
49.7
2.5

85.2
2.8
21.5
7.5
47.5
44.5
3.7

(47)
(1)
(16)
(2)
(29)
(27)
(1)

(270)
(6)
(59)
(30)
(184)
(157)
(8)

(364)
(12)
(92)
(32)
(203)
(190)
(16)

a Mean

6 SD.
*p 5 0.01–0.05.
**p 5 0.01
***p 5 0.06–0.1.
b Comparison group.
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ever had genital warts, and were more likely to
have been positive for HR-HPV. HSIL cases were
more likely than LSIL cases and controls to report
infidelity by their male partner. Neither ever
smokers nor current smokers were at increased
risk of SIL in these data.
As anticipated in this study of family planning
clients, more than 80% had ever used OC. Less
than 3% had ever used IUDs, 21% had used injectables, 8% had used Norplant, and 52% had
ever used barrier methods regularly for 6 months
or longer. The majority of barrier methods used
were condoms and spermicide, and 3% of all sub-

TABLE 2.

CONTRACEPTIVE U SE

Regular contraceptive usea
Ever barrier userb
Never
Duration of barrier method
use (years) b
,5 years
5–9.5 years
$10 years
Age at first barrier method
use (years)b
#16 years
17–18 years
.18 years
Recency of barrier method useb
Current user
Past user (.1 year since last use)
Ever oral contraceptive userd
Never usere
Duration of OC use (years)d
,5 years
5–9.5 years
$10 years
Age at first OC used
#16 years
17–18 years
.19 years
Recency of OC use
Current user
Past user (.1 years since last use)
Ever used injectablesd
Never user
Duration of injectable use (years)d
Ever used Norplant d
Never user
Duration of Norplant use (years)d

BY

TYPE

jects had ever used a diaphragm. SIL development was not significantly associated with ever
use of any specific contraceptive (Table 1).
Table 2 presents our more detailed evaluation
of SIL risk associated with contraceptive use by
type, duration, age at first use, and recency (OC
use only), adjusting for HPV, age, age at first sexual intercourse, and other contraceptives. Neither
duration of OC use, recency, nor age at first use
was associated with HSIL or LSIL risk. Similarly,
no attribute of injectables or Norplant use was associated with HSIL or LSIL risk. Ever barrier
method use, a young age (#16 years) at first bar-

CERVICAL SIL RISK : ADJUSTED ODDS RATIO
CHARACTERISTICS OF U SE

AND

AND

95% CI

FOR

Adjusted odds ratio (95% CI)

HSIL
(n 5 60)

LSIL
(n 5 316)

Controls
(n 5 427)

HSIL vs. controls

LSIL vs. controls

29
31
5.0 6 3.8

184
132
4.9 6 4.3

203
224
6.1 6 5.0

0.9 (0.5, 1.6)
1.0 Ref c
0.97 (0.90, 1.05)

1.3 (1.0, 1.8)
1.0 Ref
0.99 (0.96, 1.03)

16
9
4
16.1 6 2.1

104
57
23
17.5 6 3.6

90
65
48
19.0 6 4.7

0.9 (0.4, 1.9)
0.8 (0.3–1.8)
0.7 (0.2, 2.3)
0.98 (0.95, 1.01)

1.2 (0.8, 1.7)
1.0 (0.6, 1.6)
0.7 (0.4, 1.3)
1.01 (0.99, 1.03)

17
8
4

85
58
41

64
64
75

1.4 (0.7, 3.0)
0.7 (0.3, 1.8)
0.4 (0.1, 1.2)

1.7 (1.1, 2.5)
1.3 (0.8, 2.0)
1.0 (0.6, 1.5)

19
10
47
13
5.7 6 4.9
24
12
11
17.3 6 2.6
22
14
11

135
49
270
46
5.8 6 4.1
118
105
46
17.3 6 2.8
114
92
64

130
73
364
63
7.7 6 5.4
132
108
124
17.8 6 2.9
125
128
111

0.8 (0.4, 1.60)
1.1 (0.5, 2.5)
0.9 (0.4, 1.9)
1.0 Ref
0.96 (0.88, 1.04)
1.1 (0.5, 2.6)
0.7 (0.3–1.9)
0.8 (0.3, 2.8)
0.99 (0.95, 1.04)
0.9 (0.4, 2.1)
0.9 (0.3, 2.2)
0.8 (0.3, 2.1)

1.4 (1.0, 2.0)
1.1 (0.7, 1.7)
1.3 (0.8, 2.0)
1.0 Ref
0.97 (0.93, 1.01)
1.2 (0.7, 2.0)
1.6 (0.9, 2.6)
0.7 (0.4, 1.3)
1.01 (0.99, 1.04)
1.3 (0.8, 2.2)
1.3 (0.8, 2.2)
1.2 (0.7, 2.0)

34
13
16
44
1.6 6 1.0
2
58
4.5 6 0.7

172
98
58
258
2.0 6 3.0
30
286
2.5 6 1.3

212
152
92
335
1.7 6 1.1
32
395
3.0 6 1.4

0.9 (04, 2.0)
0.7 (0.3, 1.9)
1.1 (0.6, 2.3)
1.00 Ref
1.14 (0.80, 1.61)
0.5 (0.1, 2.2)
1.0
0.95 (0.90, 141)

1.3 (0.8, 2.0)
1.3 (0.8, 2.1)
0.7 (0.5, 1.1)
1.00 Ref
1.03 (0.95, 1.11)
1.3 (0.7, 2.2)
Ref
1.00 (0.84, 1.20)

a Regular

use defined as consistent use for at least 6 months.
for hormonal contraceptive use, age, age at first sexual intercourse, and high-risk HPV.
cReferent group.
d Adjusted for barrier contraceptive use, age, age at first sexual intercourse, and high-risk HPV.
eReferent group is never contraptive use by type.
bAdjusted

Hosted in the Center for Research on Violence Against Women institutional repository with written permission from Mary Ann Liebert, publishers.

446

COKER ET AL.

rier method use, and current barrier method use
(aRR 5 1.4; 95% CI 1.0, 2.0) were associated with
LSIL risk. However, increasing duration of barrier method use (in years) was not associated with
LSIL risk (aOR 5 0.99; 95% CI 0.96,1.03).
To evaluate whether study results differed by
the interview mode (phone versus face-to-face interview), we calculated adjusted odds ratios (OR)
for the association between SIL (HSIL and LSIL
combined) and duration of contraceptive use. The
OR for SIL risk and duration of OC use, adjusted
for age, HR-HPV, age at first sexual intercourse,
and barrier method use, among those interviewed by phone was 0.97 (95% CI 0.93, 1.02) and
among those completing face to face interview
was also 0.97 (95% CI 0.91, 1.04). Similarly the
aOR for SIL risk and duration of barrier method
use among those completing phone interviews
was 1.01 (96% CI 0.97, 1.09) and was 0.98 (95% CI
0.91, 1.05) for those completing face-to-face interviews.
Because HR-HPV positivity may modify the
association between contraceptive use and SIL
risk, we stratified analyses by HR-HPV-positive
and HR-HPV-negative cases and controls (Table
3). Because of limited study power to detect

TABLE 3.

CONTRACEPTIVE USE PATTERNS

meaningful differences in SIL risk by grade and
by HR-HPV positivity, we combined HSIL and
LSIL for this subanalysis. Ever barrier method use
was associated with an increased risk of SIL
among HR-HPV-negative cases and controls
(aOR 5 1.5; 95% CI 1.0, 2.1), yet increasing duration of barrier method use was not associated
with SIL risk among HR-HPV-negative women.
Increasing duration of barrier method use was associated with a reduced SIL risk among HR-HPVpositive cases and controls (aOR 5 0.89; 95% CI
0.81, 0.98) and this was specifically true for
longer-term use ($10 years). Early (,age 16) and
recent barrier method use was associated with a
slight increase in SIL risk among HR-HPV-negative women. Neither OC, injectables, nor Norplant use was associated with SIL risk among HRHPV-positive or HR-HPV-negative women.
We additionally explored whether protection
afforded by longer duration barrier method use
among HR-HPV-positive women differed for
those having one or two lifetime sex partners
compared with women having three or more sex
partners. Women having one or two lifetime sex
partners were less likely to use barrier methods
for 5 or more years (p 5 0.04). Among those HR-

AND

CERVICAL SIL RISK

BY

HR-HPV POSITIVITY

Adjusted odds ratio (95% CI)
Contraceptive use by type
Ever contraceptive use
Barrier methods a
Oral contraceptivesb
Duration of contraceptive use (years)
Barrier methods (continuous)a
,5
5–9.5
$10
Oral contraceptives (continuous)b
,5
5–9.5
$10
Age at fist OC use (years)
#16
17–18
191
Age at first barrier method use (years)
#16
17–18
191
a Adjusted
bAdjusted

HR-HPV positive
(181 SIL cases/79 controls)

HR-HPV negative
(195 SIL cses/348 controls)

0.8 (0.5, 1.4)
1.4 (0.6, 3.0)

1.5 (1.0, 2.1)
1.1 (0.7, 1.8)

0.89 (0.81, 0.98)
0.8 (0.4, 1.6)
0.5 (0.2, 1.1)
0.3 (0.1, 0.9)
0.91 (0.81, 1.01)
1.5 (0.6, 3.6)
1.0 (0.4, 2.6)
0.6 (0.2, 2.2)

0.97 (0.92, 1.02)
1.4 (0.9–2.3)
1.4 (0.8, 2.3)
1.0 (0.5, 1.9)
0.95 (0.91, 1.00)
1.0 (0.6, 1.8)
1.6 (0.9, 2.8)
0.7 (0.3, 1.3)

1.8 (0.7, 4.8)
2.2 (0.8, 6.4)
2.0 (0.7, 5.9)

1.5 (0.8, 3.0)
1.6 (0.8, 3.0)
1.3 (0.7, 2.5)

1.8 (0.7, 4.7)
2.0 (0.8, 5.3)
0.9 (0.3, 2.3)

2.3 (1.2, 4.2)
1.6 (0.9, 2.9)
1.4 (0.8, 2.5)

for hormonal contraceptive use, age, and age at first sex.
for barrier contraceptive use, age, and age at first use.
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HPV-positive women having one or two sex partners and adjusting for age, age at first sex, and
duration of OC use, the aOR for SIL risk and duration of barrier methods was 0.79 (95% CI 0.55,
1.14), whereas the aOR among those with three
or more sex partners was 0.91 (95% CI 0.84, 0.98).
The p value for the Breslow-Day test for homogeneity of the OR across strata of number of sex
partner of 0.41 did not indicate that aOR differed
significantly by number of lifetime sex partners.

DISCUSSION
Our finding that barrier method use may reduce
the risk of SIL development among HR-HPV-positive women is consistent with the literature 12 and
is important, as it suggests that increased duration
of barrier method use may be particularly useful
in preventing SIL development even when women
are HR-HPV positive. We found that first barrier
method use earlier in one’s life (,age 16) was associated with an increased risk of LSIL, whereas a
later age at first barrier method use was associated
with a reduced risk, particularly for HSIL, even
when adjusting for the age at first sexual intercourse. Women beginning sexual activity earlier
may be less likely to use effective methods first
(barrier methods). Early intercourse may be so
strongly correlated with early barrier method use
that we cannot remove the residual confounding
effect of age at first intercourse. However, we observe that when controlling for duration of OC use
and age at first sex, longer duration of barrier
method use is associated with a reduced SIL risk
among HR-HPV-positive women. Consistent protection of the cervix by a barrier method (primarily condoms in these data) may confer protection
even when the woman is already HR-HPV positive because the cervix is not repeatedly exposed
to an HR-HPV-positive partner. This finding is important as it suggests that consistent condom use
may protect a woman from developing cervical
neoplasia perhaps by decreasing the chances of
additional HR-HPV exposure. Undoubtedly, our
method of barrier method use is misclassified. We
cannot establish that partners of women used condoms consistently (during each sex act) and that
condoms did not break. We have a general measure of barrier method use by age at first and last
use as well as duration of use. We hypothesize,
however, that longer-duration condom users may
be more consistent users, thus, longer-duration
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barrier method use may be associated with a reduced risk of SIL, particularly among HR-HPVpositive women.
We did not find that OC use was consistently
associated with SIL risk. This finding is consistent with several past studies addressing
SIL,13,14,16– 18,24 yet differs from several others.9,15,20– 22,25 In a large case-control study of cervical intraepithelial neoplasia (CIN) among
young women (,40 years of age), Cuzick et al.20
found that shorter duration of OC use was associated with SIL risk. Although the majority of
case-control or cohort studies did not conduct
analyses by HR-HPV strata, Kjaer et al.12 were
able to conduct such a stratified analysis and
found that early age at first use of OC (#16 years
of age) was associated with an increased risk of
SIL only among HPV-negative women. Longer
duration of OC use was not associated with SIL
risk by HR-HPV strata. Many of the studies finding an association between longer-duration OC
use and cervical neoplasia specifically addressed
HSIL or invasive cancer.3,21–22,25 We had few
women with higher-grade SIL lesions.
Our finding that injectable contraception was
not associated with an increased risk of HSIL or
LSIL is consistent with the existing literature. As
reviewed by LaVecchia, 44 injectable contraceptives have not been consistently linked to CIS or
ICC,45–47 yet few studies have addressed injectable contraception and SIL risk. Like Mascarenhas et al., 48 we did not find that Norplant
use was associated with SIL risk, yet caution must
be applied in evaluating our findings for Norplant use as so few women (6%) used Norplant
beyond 2 years. Larger studies with longer follow-up periods are needed to address this question adequately.
In these data, we do not find racial differences
in risk of HSIL or SIL. This may be a function of
our including only low-income women. If racial
differences in risk of SIL exist, the reasons for the
differences are likely to be a function of differences in risk of exposure or likelihood of being
detected as having disease—not in biological differences between races.
This study has several limitations. Our study
power is limited because of the anticipated large
proportion of women using OC (80%) and the
smaller proportions using injectables (20%) or
Norplant (8%) and for the HSIL subanalysis.
However, we do have .80% power to detect a 2fold difference in LSIL risk for OC use, barrier
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method use, and injectable contraceptive use. We
did not ask women about the specific dose of OC
and, therefore, cannot assess its association with
SIL risk. When we began this study, Digene’s Hybrid Capture II was not available. Hybrid Capture I is less sensitive and specific than Hybrid
Capture II and certainly less sensitive than PCRbased methods of HPV detection. The misclassification introduced by our using this less sensitive and specific measure of HR-HPV positivity
is likely to affect HPV infection with low viral
load (those not strongly positive). With additional funding, we plan to reanalyze the HR-HPV
results using Hybrid Capture II.
This study has important methodological
strengths also deserving mention. Cases and controls were sampled from the same population,
low-income women seeking family planning services. Thus, the potential for selection bias in this
case-control study is reduced. We collected cervical samples and can control for the potentially
confounding or modifying effect of HR-HPV positivity on SIL risk. We assessed the association between SIL risk and the range of contraceptive
methods currently available and controlled for
the potentially confounding effect of other
method use (specifically barrier method use
when assessing hormonal methods) in logistic regression models. Finally, we add to the existing
literature by providing one of the first studies to
explore Norplant use and SIL risk using a casecontrol design and controlling for HR-HPV positivity. Based on these data, we do not find that
any of the range of contraceptive methods assessed was associated with an increased SIL risk.
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